Blood test may predict immunotherapy response in aggressive breast cancer
NCT ID NCT05914961
First seen Feb 15, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study is for women with triple-negative breast cancer, either early-stage or advanced, who are receiving immunotherapy. Researchers want to see if changes in a blood marker called CRP can predict how well the cancer responds to treatment. The goal is to find a simple way to guide therapy decisions without extra invasive procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Women's Health
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.